Full Press Release Details
Membrane Dynamics/Exosomes Elevated cell motility associated invasion and metastasis IMM20059 (anti EPN1 antibody) Metabolism High demand for materials supporting rapid tumor expansion Growth signaling 2. Immune Modulation Novel Targets 3. Discovery Engine Soluble and membrane-associated ectopically expressed factors that perpetuate rapid proliferation of tumor cells Extracellular Matrix (ECM) Extracellular Matrix 4.
J. Cell Mol. Cell Biol. 2016;8 (5):426 2.Wei et al. J. Cell Mol. Med. 2016;00 :1 5000 LungRenalLiverBreastSkinOvarian 4000 3000 2000 1000 0 A549 786O HuH7 MDA SKMEL28 SKOV3 MB231 IMM-ONC-01 Program Summary A Novel Antibody Targeting IL-38 IL-38 is a member of the IL-1 family of cytokines Preclinical research confirms the mechanism of action and demonstrates efficacy of IMM-ONC-01 as a monotherapy Gene expression profiling of patient tumors suggest normal IL-38 biology is co-opted by tumors of squamous origin to suppress immune infiltration2 IMM-ONC-01 Exhibits favorable pharmacokinetic profile in primates Is well tolerated in cynomolgus monkey toxicology studies Structure of human IL-381 IND filing anticipated in mid 2023 1.
B cells: Critical Players in Tumor Immunity B cell infiltration more closely associated with survival than T cell presence in multiple cancers Success of IO therapies appears to be associated with coordinated response including B cells and TLS in the unique context of each patient's tumor microenvironment Specificity of the B cell immune repertoire has not been explored beyond known tumor antigens Copyright 2022 Immunome, Inc.
Bamlanivimab (https://www. fda.gov/media/147629/dow 40 nload) GSK/VIR4 2. REGN-CoV (https://www.fda.gov/media /145610/download) 3. Bamlanivimab & etesevimab (https://www.fda.gov/media LLY 3 20 EUA Revoked/Limited REGN 2 /145801/download) 4. Sotrovimab (https://www.fda.gov/media /149532/download) LLY1 5. Evusheld (https://www.fda.gov/media /154701/download) 2019-DEC 2020-MAY 2020-OCT 2021-MAR 2021-AUG 2022-JAN 2022-JUN 2022-NOV 6.
Pero et al DOI: 10.1002/cti2.1409 ; Nikitin et al Sci Immunology DOI: 10.1126/sciimmunol.abl9943; Kinker et al doi: 10.3389/fcell.2021.678127; DeFalco et al DOI: 10.1016/j.clim.2017.10.002; Bushey et al DOI: 10.1016/j.celrep.2016.04.038; Apoptotic tumor cell SchloBer et al DOI: 10.1080/2162402X.2018.1512458; Rajan DOI: 10.1007/978-981-15-4494-1_18 https://www.globenewswire.com/en/news-release/2022/05/23/2448585/0/en/Monoclonal-Antibodies-Market-Size-to-Hit-US-524-68-Bn-By-2030.html 2.
Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind. 2 and reports with the SEC. Copyright 2022 Immunome, Inc.
These statements and predictions involve risks and uncertainties based on various factors and evolution over time and, therefore, actual dates for these milestones may differ. In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S.
While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information. We make statements and predictions about future dates for achievement of milestones related to our platform and our programs in this presentation.
This presentation may contain product names, trade names, trademarks and service marks of Immunome and of other organizations, which are the properties of their respective owners. Statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation, including independent market research, industry publications and surveys, governmental agency publications and other publicly available information.
Factors that could cause actual results to differ include, but are not limited to, the following: our ability to execute on our strategy, including with respect to R&D efforts, IND submissions and other regulatory filings, timing of these filings and the timing and nature of governmental authority feedback regarding the same, initiation and completion of any clinical studies, confirmatory testing and other anticipated milestones as and when anticipated; the fact that research and development data are subject to differing interpretations and assessments, including during the peer review/publication process in the scientific community and by regulatory authorities; whether our data will be published in a scientific journal and, if so, when and with what modifications; the effectiveness of our product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with earlier-published data and/or data used for advancing the product candidates; the fact that changes in the profile of the diseases that our programs target could emerge that could impact our ability to address those changes; our ability to fund operations; our reliance on vendors; our ability to execute on our plans for collaborations and partnerships; the competitive landscape; the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 28, 2022, and elsewhere in Immunome's Quarterly Reports on form 10-Q and other filings All statements contained in this presentation are made as of the date specified on the cover, and we undertake no duty to publicly update or revise any such statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.
Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "suggest," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.